| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
QuantaMatrix Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,500.00 |
| 52 Week High | ₩7,900.00 |
| 52 Week Low | ₩3,360.00 |
| Beta | 0.095 |
| 11 Month Change | 8.70% |
| 3 Month Change | 22.78% |
| 1 Year Change | -7.02% |
| 33 Year Change | -68.53% |
| 5 Year Change | n/a |
| Change since IPO | -81.33% |
Recent News & Updates
Is QuantaMatrix (KOSDAQ:317690) Using Debt In A Risky Way?
Jul 19
What Type Of Shareholders Make Up QuantaMatrix Inc.'s (KOSDAQ:317690) Share Registry?
Mar 10Shareholder Returns
| A317690 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 12.8% | 0.8% | -2.4% |
| 1Y | -7.0% | 26.2% | 5.4% |
Return vs Industry: A317690 underperformed the KR Biotechs industry which returned 26.2% over the past year.
Return vs Market: A317690 underperformed the KR Market which returned 5.4% over the past year.
Price Volatility
| A317690 volatility | |
|---|---|
| A317690 Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in KR Market | 11.1% |
| 10% least volatile stocks in KR Market | 2.2% |
Stable Share Price: A317690 has not had significant price volatility in the past 3 months.
Volatility Over Time: A317690's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 103 | Sung Hoon Kwon | www.quantamatrix.com |
QuantaMatrix Inc. operates as an in-vitro diagnostics company in South Korea. Its products include dRAST, a direct and rapid antimicrobial susceptibility test for treating sepsis that provides MIC-based phenotypic antimicrobial susceptibility testing direct from positive blood culture; QDST, a rapid phenotypic drug susceptibility testing system for tuberculosis; QPLEX Alz plus assay, an early diagnosis kit for Alzheimer's disease; and Quanti9 and QuantiGal, a prognostic prediction kit for cardiovascular diseases. The company was founded in 2010 and is based in Seoul, South Korea.
QuantaMatrix Inc. Fundamentals Summary
| A317690 fundamental statistics | |
|---|---|
| Market cap | ₩71.77b |
| Earnings (TTM) | -₩20.22b |
| Revenue (TTM) | ₩3.48b |
21.4x
P/S Ratio-3.7x
P/E RatioIs A317690 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A317690 income statement (TTM) | |
|---|---|
| Revenue | ₩3.48b |
| Cost of Revenue | ₩2.41b |
| Gross Profit | ₩1.07b |
| Other Expenses | ₩21.29b |
| Earnings | -₩20.22b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.22k |
| Gross Margin | 30.69% |
| Net Profit Margin | -580.48% |
| Debt/Equity Ratio | 40.2% |
How did A317690 perform over the long term?
See historical performance and comparison